META Pharmaceuticals’ META-001-PH Receives the US FDA’s Rare Pediatric Disease Designation to Treat Primary Hyperoxaluria
Shots:
- The US FDA has granted RPDD to the company’s META-001-PH (oral, daily) for treating primary hyperoxaluria (PH)
- META-001-PH has reduced urinary oxalate excretion by up to 80% and depicted favorable safety & tolerability in non-clinical studies and is currently under IND-enabling toxicology studies. Its P-I among healthy individuals is anticipated during H1’25 in Australia
- META-001-PH is a small molecule that has been developed under partnership using META's chemistry team and XtalPi's AI drug discovery team, from initial screening to nomination
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
